Epsilon M&A Deal Report - PrecisionBiotics Group
Transaction Multiples for the Valuation of Private Companies
Novozymes / PrecisionBiotics Group
No EMAT :
101039
Announced Date :
25/06/2020
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Novozymes
Target :
PrecisionBiotics Group
Country :
Ireland
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
- Food Producers > Food & Beverage Industry > Food Complements
Business Description :
Founded in 1999, PrecisionBiotics Group is focused on the discovery, development, and commercialization of proprietary probiotic and pharmabiotic treatments. > Products include: Alflorex®: Alflorex,...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
||||
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 128
- Number of EMAT Reports / sub-sector « Food Complements » = 116
| Date | Acquirer | Target | Country | Multiples | See details |
| 01/11/2015 | BFS Group | Caterfood Holdings | England | *** | 100883 |
| 02/04/2019 | Abattis Bioceuticals | Pro Natura | Netherlands | * | 100846 |
Source: Epsilon Research / EMAT
